Pipeline · VNQ-330Active studySynthetic mock data
VNQ-330 — PD-1 × LAG-3
Bispecific · Hepatocellular · Phase Ib
Modality
Bispecific
Target
PD-1 × LAG-3
Phase
Phase Ib
Toxicity flags
1
Mechanism
VNQ-330 is a bispecific engineered to engage PD-1 × LAG-3 with the goal of a clinically meaningful response in Hepatocellular. Currently in Phase Ib; next milestone: Phase II protocol draft.
Dose-escalation cohorts
| Dose | Cohort N | DLTs | Status |
|---|---|---|---|
| 200 mg q3w | 6 | 0 | cleared |
| 400 mg q3w | 6 | 1 | cleared |
| 800 mg q3w | 12 | 1 | expanding |
Recent toxicity events
1 active| Date | Case | Grade | Term | Resolved |
|---|---|---|---|---|
| 2026-04-16 | F4407-LIV-208 | G2 | Hepatic enzyme increased | Resolved |
Linked studies
Cross-links